• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于A4筛查数据,通过机器学习算法预测淀粉样蛋白风险:在日本试验就绪队列研究中的应用。

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study.

作者信息

Sato Kenichiro, Ihara Ryoko, Suzuki Kazushi, Niimi Yoshiki, Toda Tatsushi, Jimenez-Maggiora Gustavo, Langford Oliver, Donohue Michael C, Raman Rema, Aisen Paul S, Sperling Reisa A, Iwata Atsushi, Iwatsubo Takeshi

机构信息

Department of Neurology Graduate School of Medicine The University of Tokyo Tokyo Japan.

Department of Neuropathology Graduate School of Medicine The University of Tokyo Tokyo Japan.

出版信息

Alzheimers Dement (N Y). 2021 Mar 24;7(1):e12135. doi: 10.1002/trc2.12135. eCollection 2021.

DOI:10.1002/trc2.12135
PMID:33778148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7988864/
Abstract

BACKGROUND

Selecting cognitively normal elderly individuals with higher risk of brain amyloid deposition is critical to the success of prevention trials for Alzheimer's disease (AD).

METHODS

Based on the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease study data, we built machine-learning models and applied them to our ongoing Japanese Trial-Ready Cohort (J-TRC) webstudy participants registered within the first 9 months ( = 3081) of launch to predict standard uptake value ratio (SUVr) of amyloid positron emission tomography.

RESULTS

Age, family history, online Cognitive Function Instrument and CogState scores were important predictors. In a subgroup of J-TRC webstudy participants with known amyloid status ( = 37), the predicted SUVr corresponded well with the self-reported amyloid test results (area under the curve = 0.806 [0.619-0.992]).

DISCUSSION

Our algorithms may be usable for automatic prioritization of candidate participants with higher amyloid risks to be preferentially recruited from the J-TRC webstudy to in-person study, maximizing efficiency for the identification of preclinical AD participants.

摘要

背景

选择脑淀粉样蛋白沉积风险较高的认知正常老年人对于阿尔茨海默病(AD)预防试验的成功至关重要。

方法

基于无症状阿尔茨海默病抗淀粉样蛋白治疗研究数据,我们构建了机器学习模型,并将其应用于我们正在进行的日本试验就绪队列(J-TRC)网络研究参与者,这些参与者在启动后的前9个月内注册(n = 3081),以预测淀粉样蛋白正电子发射断层扫描的标准摄取值比率(SUVr)。

结果

年龄、家族史、在线认知功能仪器和CogState评分是重要的预测因素。在J-TRC网络研究中已知淀粉样蛋白状态的参与者亚组(n = 37)中,预测的SUVr与自我报告的淀粉样蛋白测试结果高度吻合(曲线下面积 = 0.806 [0.619 - 0.992])。

讨论

我们的算法可用于自动优先选择淀粉样蛋白风险较高的候选参与者,以便从J-TRC网络研究中优先招募到面对面研究中,从而最大限度地提高识别临床前AD参与者的效率。

相似文献

1
Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study.基于A4筛查数据,通过机器学习算法预测淀粉样蛋白风险:在日本试验就绪队列研究中的应用。
Alzheimers Dement (N Y). 2021 Mar 24;7(1):e12135. doi: 10.1002/trc2.12135. eCollection 2021.
2
The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.用于临床前和前驱期阿尔茨海默病的试验准备队列(TRC-PAD):前 3 年的经验。
J Prev Alzheimers Dis. 2020;7(4):234-241. doi: 10.14283/jpad.2020.47.
3
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.预测淀粉样蛋白负担以加速二级预防临床试验的招募。
J Prev Alzheimers Dis. 2020;7(4):213-218. doi: 10.14283/jpad.2020.44.
4
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.阿尔茨海默病匹配先导研究 - 远程采集用于临床前阿尔茨海默病试验的血浆生物标志物的可行性。
J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101.
5
Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD).招募参加阿尔茨海默病预防试验(APT)网络研究,以建立一个适合临床试验的队列,用于研究临床前和前驱期阿尔茨海默病(TRC-PAD)。
J Prev Alzheimers Dis. 2020;7(4):219-225. doi: 10.14283/jpad.2020.46.
6
The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview.临床试验准备队列用于临床前/前驱阿尔茨海默病(TRC-PAD)项目:概述。
J Prev Alzheimers Dis. 2020;7(4):208-212. doi: 10.14283/jpad.2020.45.
7
Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies.队列特异性优化预测临床前阿尔茨海默病模型,以提高临床前阿尔茨海默病研究中期的筛查性能。
J Prev Alzheimers Dis. 2021;8(4):503-512. doi: 10.14283/jpad.2021.39.
8
Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer's Disease in Japan.公众对日本阿尔茨海默病抗淀粉样蛋白治疗的医疗保健准备情况的看法。
Alzheimers Res Ther. 2024 Oct 3;16(1):205. doi: 10.1186/s13195-024-01568-8.
9
Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults: A Machine Learning Approach Using A4 Data.使用 A4 数据预测认知正常的老年人中的淀粉样蛋白阳性:一种机器学习方法。
Neurology. 2022 Jun 14;98(24):e2425-e2435. doi: 10.1212/WNL.0000000000200553. Epub 2022 Apr 25.
10
TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology.TRC-PAD:通过创新信息技术加速 AD 临床试验的招募。
J Prev Alzheimers Dis. 2020;7(4):226-233. doi: 10.14283/jpad.2020.48.

引用本文的文献

1
Factors affecting participation in web-based Alzheimer's questionnaire surveys: Lessons from the Japanese trial-ready cohort.影响参与基于网络的阿尔茨海默病问卷调查的因素:来自日本试验就绪队列的经验教训。
JAR Life. 2025 Mar 3;14:100008. doi: 10.1016/j.jarlif.2025.100008. eCollection 2025.
2
Predicting amyloid beta accumulation in cognitively unimpaired older adults: Cognitive assessments provide no additional utility beyond demographic and genetic factors.预测认知功能未受损的老年人中β淀粉样蛋白的积累:除人口统计学和遗传因素外,认知评估并无额外作用。
Alzheimers Dement. 2025 Mar;21(3):e70036. doi: 10.1002/alz.70036.
3
Blood-based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost-effectiveness in Alzheimer's disease prevention studies.

本文引用的文献

1
TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology.TRC-PAD:通过创新信息技术加速 AD 临床试验的招募。
J Prev Alzheimers Dis. 2020;7(4):226-233. doi: 10.14283/jpad.2020.48.
2
Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.预测淀粉样蛋白负担以加速二级预防临床试验的招募。
J Prev Alzheimers Dis. 2020;7(4):213-218. doi: 10.14283/jpad.2020.44.
3
The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview.
基于血液的生物标志物预筛查:不同检测组合及临界值的模拟研究——一项关于阿尔茨海默病预防研究中有效性和成本效益的考察
Alzheimers Dement (N Y). 2025 Mar 10;11(1):e70065. doi: 10.1002/trc2.70065. eCollection 2025 Jan-Mar.
4
Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer's Disease in Japan.公众对日本阿尔茨海默病抗淀粉样蛋白治疗的医疗保健准备情况的看法。
Alzheimers Res Ther. 2024 Oct 3;16(1):205. doi: 10.1186/s13195-024-01568-8.
5
Artificial intelligence for optimizing recruitment and retention in clinical trials: a scoping review.人工智能在临床试验中优化招募和保留的应用:范围综述。
J Am Med Inform Assoc. 2024 Nov 1;31(11):2749-2759. doi: 10.1093/jamia/ocae243.
6
Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.联合检测血浆 Aβ和 p-tau217 可提高对非痴呆老年人脑淀粉样蛋白的检测效果。
Alzheimers Res Ther. 2024 May 23;16(1):115. doi: 10.1186/s13195-024-01469-w.
7
Predicting positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors.利用可解释的机器学习模型,结合可穿戴传感器数据和生活方式因素,预测正电子发射断层扫描脑淀粉样蛋白阳性。
Alzheimers Res Ther. 2023 Dec 12;15(1):212. doi: 10.1186/s13195-023-01363-x.
8
Predicting amyloid-beta pathology in the general population.预测一般人群中的淀粉样β病理学。
Alzheimers Dement. 2023 Dec;19(12):5506-5517. doi: 10.1002/alz.13161. Epub 2023 Jun 11.
9
Computerized cognitive practice effects in relation to amyloid and tau in preclinical Alzheimer's disease: Results from a multi-site cohort.计算机化认知训练对临床前阿尔茨海默病中淀粉样蛋白和tau蛋白的影响:一项多中心队列研究结果
Alzheimers Dement (Amst). 2023 Mar 20;15(1):e12414. doi: 10.1002/dad2.12414. eCollection 2023 Jan-Mar.
10
Molecular Pathogenesis and Disease-modifying Therapies of Alzheimer's Disease and Related Disorders.阿尔茨海默病及相关疾病的分子发病机制与疾病修饰疗法
JMA J. 2022 Jul 15;5(3):307-313. doi: 10.31662/jmaj.2022-0079. Epub 2022 Jun 17.
临床试验准备队列用于临床前/前驱阿尔茨海默病(TRC-PAD)项目:概述。
J Prev Alzheimers Dis. 2020;7(4):208-212. doi: 10.14283/jpad.2020.45.
4
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.与临床正常老年人淀粉样蛋白负担增加相关的因素。
JAMA Neurol. 2020 Jun 1;77(6):735-745. doi: 10.1001/jamaneurol.2020.0387.
5
Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings.欧洲预防阿尔茨海默病(EPAD)试验预备队列的预筛选:AD 风险因素和招募环境的影响。
Alzheimers Res Ther. 2020 Jan 6;12(1):8. doi: 10.1186/s13195-019-0576-y.
6
A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models.系统评价显示,机器学习在临床预测模型中并未优于逻辑回归。
J Clin Epidemiol. 2019 Jun;110:12-22. doi: 10.1016/j.jclinepi.2019.02.004. Epub 2019 Feb 11.
7
Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis.降低临床前 AD 试验的招募成本:脑淀粉样变性自动预筛选算法的验证。
Stat Methods Med Res. 2020 Jan;29(1):151-164. doi: 10.1177/0962280218823036. Epub 2019 Jan 30.
8
Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort.日本阿尔茨海默病神经影像计划队列中临床前期阿尔茨海默病的临床和认知特征。
Alzheimers Dement (N Y). 2018 Nov 26;4:645-651. doi: 10.1016/j.trci.2018.10.004. eCollection 2018.
9
The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials.美国国家老龄化研究所-阿尔茨海默病协会阿尔茨海默病框架:临床试验应用。
Alzheimers Dement. 2019 Jan;15(1):172-178. doi: 10.1016/j.jalz.2018.05.006. Epub 2018 Jun 21.
10
Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.日本和北美阿尔茨海默病神经影像学倡议研究:为国际试验进行协调。
Alzheimers Dement. 2018 Aug;14(8):1077-1087. doi: 10.1016/j.jalz.2018.03.009. Epub 2018 May 9.